IL15 and neoplasm: GT-00AxIL15 also synergized with approved ADCC-mediating αEGFR or αPD-L1 mAbs in vitro and induced significant anti-tumor activity in combination with αPD-L1 treatment in a melanoma model that is non- or minimally responsive to IL-15 or αPD-L1/PD-1 monotherapy [41].